Organon APAC Head On Why World Needs A Company Dedicated To Women’s Health
Executive Summary
In this audio interview, Organon’s head for the Asia Pacific region talks to Scrip on the company’s ambitions in the women’s health segment and the outlook for its biosimilars and established brands portfolios.
Kaja Natland, Organon’s head for the Asia Pacific region including Japan, tells Scrip why the world needs a specialist women’s health company, underscoring there’s no other healthcare firm with the kind of global footprint that the Merck & Co., Inc. spin-out brings and which is dedicated to “putting women at the center.”
Kaja Natland
Currently, Organon’s portfolio comprises over 60 medicines and products that cater to more than 140 markets, with about 80% of its $6.5bn in global revenues coming from outside the US. Shares of Organon commenced trading on the New York Stock Exchange on 3 June.
Expanding beyond just reproductive health, a renewed focus on the established brands portfolio and investments in the life cycle management of such products are some of the other aspects Natland touched upon. The under-diagnosis and treatment of cardiovascular disease in women also presents a significant opportunity to drive growth for the firm’s established cardiac therapies, she indicated.
The executive in addition expects the pre-spin-out acquisition of the commercial-stage medical device company Alydia Health to be a core pillar to becoming a leading women’s health player. Alydia brings with it the Jada System, a device designed to encourage normal contraction of the uterus to stop excessive bleeding after childbirth.
Podcast Time Stamps
00:08 Introduction
01:01 The spin-off from Merck: The world needs a company like Organon
03:13 Taking a broad view on women’s health - beyond reproductive health
05:24 Wall of Voices – Listening to the needs and challenges of women
10:32 Partnering and Inorganic Growth
12:51 The cultural fit for alliances
14:06 Majority-female board of directors
15:50 Renewed focus on established products portfolio, life cycle management
19:07 Biosimilars franchise
21:30 Putting women’s health high up on the agenda
These and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud and TuneIn - and also now on Spotify Podcasts - and via smart speakers if one of these platforms has been set up as your default podcast provider.
Related Stories:
https://generics.pharmaintelligence.informa.com/GB150975/Organon-Completes-Spin-Out-From-Merck-With-Five-Biosimilars